Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.

Jauw YWS, Huisman MC, Nayak TK, Vugts DJ, Christen R, Naegelen VM, Ruettinger D, Heil F, Lammertsma AA, Verheul HMW, Hoekstra OS, van Dongen GAMS, Menke-van der Houven van Oordt CW.

EJNMMI Res. 2018 Jan 22;8(1):6. doi: 10.1186/s13550-018-0358-8.

2.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.

Hidalgo M, Martinez-Garcia M, Le Tourneau C, Massard C, Garralda E, Boni V, Taus A, Albanell J, Sablin MP, Alt M, Bahleda R, Varga A, Boetsch C, Franjkovic I, Heil F, Lahr A, Lechner K, Morel A, Nayak T, Rossomanno S, Smart K, Stubenrauch K, Krieter O.

Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. doi: 10.1158/1078-0432.CCR-17-1588. Epub 2017 Dec 7.

PMID:
29217526
3.

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.

Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C.

Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098.

4.

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.

Birzele F, Voss E, Nopora A, Honold K, Heil F, Lohmann S, Verheul H, Le Tourneau C, Delord JP, van Herpen C, Mahalingam D, Coveler AL, Meresse V, Weigand S, Runza V, Cannarile M.

Clin Cancer Res. 2015 Jun 15;21(12):2753-62. doi: 10.1158/1078-0432.CCR-14-2141. Epub 2015 Mar 11.

5.

[Practical help in the validation process].

Heil FJ.

Z Gastroenterol. 2014 Sep;52(9):1119. German. No abstract available.

PMID:
25340209
6.

[Enhancements and new features -- correct coding].

Heil FJ, Tappe U.

Z Gastroenterol. 2014 Apr;52(4):394-5. German. No abstract available.

PMID:
25006635
7.

Safety analysis of endoscopist-directed propofol sedation: a prospective, national multicenter study of 24 441 patients in German outpatient practices.

Sieg A; bng-Study-Group, Beck S, Scholl SG, Heil FJ, Gotthardt DN, Stremmel W, Rex DK, Friedrich K.

J Gastroenterol Hepatol. 2014 Mar;29(3):517-23.

PMID:
24716213
8.

[The Professional Association of Gastroenterologists Germany e. V. informed].

Heil FJ, Beyer A.

Z Gastroenterol. 2014 Jan;52(1):149. German. No abstract available.

PMID:
24571014
9.

Mountain cold-trapping increases transfer of persistent organic pollutants from atmosphere to cows' milk.

Shunthirasingham C, Wania F, MacLeod M, Lei YD, Quinn CL, Zhang X, Scheringer M, Wegmann F, Hungerbühler K, Ivemeyer S, Heil F, Klocke P, Pacepavicius G, Alaee M.

Environ Sci Technol. 2013 Aug 20;47(16):9175-81. doi: 10.1021/es400851d. Epub 2013 Aug 8.

PMID:
23885857
10.

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, Geho D, Middleton SA, Vassilev LT, Nichols GL, Bui BN.

Lancet Oncol. 2012 Nov;13(11):1133-40. doi: 10.1016/S1470-2045(12)70474-6. Epub 2012 Oct 17.

PMID:
23084521
11.

Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II.

Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers JJ, Pittet V, Vader JP, Froehlich F, Felley C; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):232-40. doi: 10.1016/j.crohns.2009.05.003. Epub 2009 Jul 15.

PMID:
21172281
12.
13.

Management factors affecting udder health and effects of a one year extension program in organic dairy herds.

Ivemeyer S, Walkenhorst M, Heil F, Notz C, Maeschli A, Butler G, Klocke P.

Animal. 2009 Nov;3(11):1596-604. doi: 10.1017/S1751731109990498.

PMID:
22444993
14.

[Effects of a two-year dairy herd health management programme on udder health, use of antibiotics and longevity].

Ivemeyer S, Maeschli A, Walkenhorst M, Klocke P, Heil F, Oser S, Notz C.

Schweiz Arch Tierheilkd. 2008 Oct;150(10):499-505. doi: 10.1024/0036-7281.150.10.499. German.

15.

[Database system for herd health management of dairy herds especially for udder health].

Ivemeyer S, Raillard D, Heil F, Klocke P.

Schweiz Arch Tierheilkd. 2007 Oct;149(10):449-56. German.

16.

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.

Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S.

Science. 2004 Mar 5;303(5663):1526-9. Epub 2004 Feb 19.

17.

The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily.

Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T, Dietrich H, Lipford G, Takeda K, Akira S, Wagner H, Bauer S.

Eur J Immunol. 2003 Nov;33(11):2987-97.

18.

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.

Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S.

Nat Immunol. 2002 Jun;3(6):499. No abstract available.

PMID:
12032557

Supplemental Content

Support Center